Discovery of an orally active non-peptide fibrinogen receptor antagonist based on the hydantoin scaffold

Antagonists of the platelet fibrinogen receptor (GP IIb/IIIa receptor) are expected to be a promising new class of antithrombotic agents. The binding of fibrinogen to the fibrinogen receptor depends on an Arg-Gly-Asp-Ser (RGD S) tetrapeptide recognition motif. Structural modifications of the RGDS lea d have led to the discovery of a non-peptide RGD mimetic GP IIb/IIIa antago nist 44 (S 1197). Compound 44 inhibited, in a dose dependent and reversible manner, human and dog platelet aggregation as well as I-125-fibrinogen bin ding to ADP-activated human gel filtered platelets and isolated GP IIb/IIIa with. K-i values of 9 nM and 0.17 nM, respectively. A pharmacophore mappin g procedure with QXP and a SD-QSAR analysis applying the GRID/GOLPE methodo logy yielded a stable, rather predictive model and revealed structural feat ures which are important for binding. Hydrophobic substitutions both at the hydantoin nucleus and at the C-terminus increase the affinity toward the f ibrinogen receptor. The crystalline ethyl ester prodrug 48 (HMR 1794) is an orally active antithrombotic agent which is a promising drug candidate for the treatment of thrombotic diseases in humans.